<DOC>
	<DOCNO>NCT01794702</DOCNO>
	<brief_summary>The goal Phase I clinical research study find high tolerable dose clofarabine give decitabine , idarubicin , cytarabine patient acute leukemia . The goal Phase II study learn decitabine follow combination clofarabine , idarubicin , cytarabine help control acute leukemia . The safety drug combination also study . Decitabine idarubicin design damage DNA ( genetic material cell ) . This may cause cancer cell die . Clofarabine design interfere growth development cancer cell . Cytarabine design insert DNA stop DNA repairing .</brief_summary>
	<brief_title>Decitabine Followed Clofarabine , Idarubicin , Cytarabine Acute Leukemia</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign study group base join study . Up 3 group 6 participant enrol Phase I portion study . Up 74 participant enrol Phase II . Phase I : If enrol Phase I portion , number day clofarabine receive depend join study . The first group participant receive clofarabine 4 day . Each new group receive clofarabine number day , intolerable side effect see . The number day may reduce 3 . The clofarabine dose per day group group . All participant receive dose level decitabine , idarubicin cytarabine . Phase II : If enrol Phase II portion , receive decitabine , idarubicin , cytarabine . You receive clofarabine high number day tolerate Phase I portion . All participant receive dose level decitabine , idarubicin , cytarabine , clofarabine . Study Drug Administration : Each study drug cycle 33 day . The first cycle study drug call Induction . If doctor think need , 2 Induction cycle . Phase I ( Induction ) : On Days 1-5 cycle , receive decitabine 1 time day vein 1 hour . On Days 6-10 cycle : - You receive cytarabine 1 time day vein 2 hour . - On Days 6-8 , receive idarubicin 1 time day vein 30 minute . - You receive clofarabine 1 time day vein 1 hour Days 6-8 6-9 , depend join study . If doctor think need , dose level reduce Induction . If doctor think need , may receive few day treatment Induction cycle ( ) . Phase II ( Induction ) : On Days 1-5 cycle , receive decitabine 1 time day vein 1 hour . On Days 6-10 cycle : - You receive cytarabine 1 time day vein 2 hour . - On Days 6-8 , receive idarubicin 1 time day vein 30 minute . - You receive clofarabine 1 time day vein 1 hour Days 6-8 6-9 , depend high number day clofarabine tolerated Phase I portion study . If doctor think need , dose level reduce Induction . If doctor think need , may receive few day treatment Induction cycle ( ) . Phases I II ( Consolidation ) : If disease respond study drug , may receive 6 study drug cycle . This call Consolidation . On Days 1-5 cycle : - You receive decitabine 1 time day vein 1 hour . On Days 6-8 cycle : - You receive cytarabine 1 time day vein 2 hour . - You receive clofarabine 1 time day vein 1 hour . - On Days 6-7 , receive idarubicin 1 time day vein 30 minute . If doctor think need , may receive few day treatment Consolidation cycle . Study Visits : Before start cycle , physical exam , include measurement vital sign . Every 3-7 day , blood ( 2 teaspoon ) draw routine test . On Day 33 every 2-3 cycle ( +/- 7 day ) , doctor think need , bone marrow aspirate check status disease . To collect bone marrow aspirate , area hip numb anesthetic , small amount bone marrow withdrawn large needle . Length Treatment : You may continue take study drug 8 cycle . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete long-term follow-up . Long-term Follow-up : Every 3 month 1 year last study drug dose , study staff call ask feeling , side effect may , drug may take . These call last 5 minute . This investigational study . Decitabine FDA approve commercially available treat myelodysplastic syndrome ( MDS ) . Clofarabine FDA approve commercially available treat ALL child . Idarubicin cytarabine FDA approve commercially available treat AML . The study drug combination investigational . Up 92 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>1 . Sign IRBapproved inform consent document . 2 . Age &gt; /= 18 year &lt; 65 year . 3 . Diagnosis AML [ acute promyelocytic leukemia ] refractory/relapsed disease ( Patients must primary refractory , relapse 1 , relapse 2 ) . NOTE : Patients AML arise prior MDS MPN would eligible even receive treatment AML . NOTE : Patients relapsed/refractory ALL would also eligible phase II part study . NOTE : Use hydroxyurea and/or 4 dos cytarabine , emergent cytoreduction allow 4 . ECOG performance status &lt; /=2 study entry . 5 . Organ function define ( unless due leukemia ) : Serum creatinine &lt; /= 3 mg/dL ; Total bilirubin &lt; /= 2.5 mg/dL ; ALT ( SGPT ) &lt; /= 3 x ULN &lt; /= 5 x ULN relate disease 6 . Cardiac ejection fraction â‰¥ 40 % ( either cardiac ECHO MUGA scan ) 7 . Women childbearing potential must negative serum urine pregnancy test within 7 day . Men must agree father child agree use condom partner child bear potential . 1 . Breast feeding woman 2 . Patients uncontrolled active infection ( viral , bacterial , fungal eligible ) . 3 . Patients active secondary malignancy eligible unless approve PI . 4 . NOTE : Prior therapy decitabine , clofarabine , idarubicin , cytarabine allow , unless prior therapy identical schema/schedule propose study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Leukemia</keyword>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>MTD</keyword>
	<keyword>Response Rate</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
	<keyword>Idarubicin</keyword>
	<keyword>Idamycin</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
</DOC>